Central serous chorioretinopathy secondary to intramuscular testosterone therapy.

Michael LockhartE AliM MustafaW TormeyS SreenanA SaaedJ H McDermott

Published in: Endocrinology, diabetes & metabolism case reports (2023)

Blurred vision in patients treated with testosterone replacement therapy (TRT) should prompt an ophthalmology review. The potential for reduced risk of central serous chorioretinopathy (CSR) with daily transdermal testosterone remains a matter of conjecture. CSR is a rare potential side effect of TRT.

Keyphrases

replacement therapy
smoking cessation
high grade
artificial intelligence
human health
physical activity
mesenchymal stem cells
risk assessment
bone marrow
deep learning